Self-aggregation protein and application thereof

By fusing self-aggregating proteins with the target enzyme gene to form insoluble aggregates, the problems of carrier compatibility and enzyme activity of immobilized enzymes are solved, realizing efficient and low-cost preparation and application of immobilized enzymes.

CN121064295APending Publication Date: 2025-12-05CHINA FORTUNE WAY CO
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202511362176.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-09-23
Publication Date
2025-12-05

AI Technical Summary

Technical Problem

Existing immobilized enzyme technologies suffer from poor carrier compatibility, poor immobilization effect, and poor enzyme activity. Furthermore, traditional methods require exogenous carriers and chemical modifications, leading to enzyme loss and high costs.

Method used

By employing self-aggregating proteins, which are linked to the target enzyme through gene fusion, insoluble aggregates are spontaneously formed, achieving endogenous immobilization, avoiding dependence on exogenous carriers, and maintaining the enzyme's native conformation and activity.

Benefits of technology

This invention achieves highly stable and compatible immobilized enzymes, simplifies the preparation process, reduces costs, improves enzyme utilization efficiency and operational stability, and is suitable for the immobilization of various industrial enzymes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The invention relates to the field of gene engineering, in particular to a self-aggregation protein and application thereof. According to the self-aggregation protein, the amino acid sequence of the self-aggregation protein is as shown in SEQ ID NO. 1. The self-aggregation protein is a specific protein tag with efficient and stable self-aggregation characteristics. The protein is the basis of all subsequent inventions (carriers, strains and immobilized enzymes), the determined sequence ensures the repeatability and reliability of the self-aggregation behavior, the uncertainty caused by using other self-aggregation proteins which are possibly low in efficiency or unknown in property is avoided, and a uniform and optimal performance standard is provided for the whole technical scheme.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of genetic engineering, and more specifically, to a self-aggregating protein and its applications. Background Technology

[0002] Biocatalysis is a crucial part of green drug synthesis, especially in the area of ​​chiral drug intermediates, where it offers significant advantages. In industrial production, enzymes are increasingly used as catalysts, but they are often single-use and difficult to recycle. However, the advent of immobilized enzyme technology has effectively solved these problems, greatly promoting the industrialization of biocatalysis.

[0003] Enzyme immobilization is divided into chemical and physical methods. Chemical methods include binding and cross-linking methods, while physical methods include adsorption and encapsulation methods. All these methods require the addition of exogenous carriers or reagents to induce enzyme molecules to bind or encapsulate with the carrier or enzyme molecule, generating immobilized enzymes, which require high preservation standards. Most importantly, not every enzyme molecule can form an immobilized enzyme; a significant amount of enzyme is lost, and carrier compatibility is lacking. Furthermore, the activity and reaction conditions of the resulting immobilized enzyme will also be altered.

[0004] Therefore, it is necessary to develop an immobilized enzyme method that has good enzyme compatibility, good immobilization effect, good immobilized enzyme activity, and good stability in repeated use.

[0005] In view of this, the present invention is hereby proposed. Summary of the Invention

[0006] The purpose of this invention is to provide a self-aggregating protein and its application to solve the problems of poor carrier compatibility, poor immobilization effect and poor enzyme activity in the existing immobilization process.

[0007] In order to achieve the above-mentioned objectives of the present invention, the following technical solution is adopted: One aspect of the present invention relates to a self-aggregating protein comprising a self-assembling peptide and an Mtu ΔI-CM+ self-cleaved inteptide, the amino acid sequence of said self-aggregating protein being shown in SEQ ID NO.1.

[0008] SEQ ID NO.1 is: YKKIIKKLALAEGTRIFDPVTGTTHRIEDVVDGRKPIHVVAAAKDGTLHARPVVSWFDQGTRDVIGLRIAGGAILWATPDHKVLTEYGWRAAGELRKGDRVAQPRRFDGFGDSAPIPARVQALADALDDKFLHDMLAEELRYSVIREVLPTRRARTFGLEVEELHTLVAEGVVVHN.

[0009] The self-aggregating protein described is a specific protein tag with efficient and stable self-aggregating properties. This protein forms the basis for all subsequent inventions (vectors, strains, immobilized enzymes). Its defined sequence ensures the reproducibility and reliability of the self-aggregating behavior, avoiding the uncertainties caused by using other potentially inefficient or undefined self-aggregating proteins, and providing a unified and optimal performance benchmark for the entire technical solution.

[0010] The self-aggregating protein described herein is endogenously immobilized without the need for an exogenous carrier: This self-aggregating protein possesses unique properties, enabling it to spontaneously and efficiently aggregate into an insoluble precipitate after expression within cells. This characteristic allows the enzyme immobilization process to be completed entirely autonomously within the cell, completely eliminating the dependence of traditional immobilization techniques on exogenous carriers and fundamentally avoiding problems such as carrier costs, carrier biocompatibility, and steric hindrance to enzyme activity.

[0011] The self-aggregating protein described above, serving as a universal "tag," can be linked to various target enzymes via gene fusion. Practical experience has demonstrated that its fusion expression with several commonly used industrial enzymes successfully achieves self-aggregation, exhibiting excellent universality and compatibility, thus becoming a universal immobilization technology platform. The protein aggregates formed after self-aggregation constitute a robust natural protein matrix. This matrix provides a protective microenvironment for the enzyme molecules, significantly enhancing the enzyme's tolerance to harsh external conditions (such as shear stress, organic solvents, and pH fluctuations), thereby laying the foundation for the high stability of the immobilized enzyme.

[0012] Self-aggregating proteins are proteins that can spontaneously transform from a soluble monomeric state into highly ordered protein aggregates through intermolecular interactions. This process is usually driven by inherent properties of the protein itself and does not require other entirely different proteins to catalyze its aggregation.

[0013] The nucleotide sequence encoding the self-aggregating protein is shown in SEQ ID NO.2.

[0014] SEQ ID NO.2 is: .

[0015] Another aspect of the present invention relates to a recombinant expression vector comprising: a nucleotide sequence encoding the self-aggregating protein and a nucleotide sequence encoding the target protein.

[0016] The recombinant expression vector combines the self-aggregating protein with the target enzyme, protecting the key genetic tool for achieving this technology. It is an "integrated" gene construct capable of simultaneously expressing the self-aggregating tag and the target enzyme through a single genetic operation, and the two fuse naturally within the cell. This simplifies the genetic construction process and ensures that the self-aggregating tag and the target enzyme can be accurately and efficiently co-expressed as a fusion protein, a prerequisite for achieving "self-aggregation immobilization."

[0017] Further, the target protein includes, but is not limited to, at least one of: transaminase, ketone reductase, monooxygenase, olefin reductase, amino acid dehydrogenase, formate dehydrogenase, or glucose dehydrogenase. In some specific embodiments, the target protein is any one of the above enzymes, or a combination of any two of the above enzymes, or a combination of any three of the above enzymes, or a combination of any four of the above enzymes, or a combination of any five of the above enzymes, or a combination of any six of the above enzymes, or a combination of any seven of the above enzymes.

[0018] The technology of this invention has broad compatibility and application potential, and is particularly suitable for many of the most important and common enzyme types in industrial production (especially enzymes that require coenzyme regeneration or participate in chiral synthesis). This invention is not limited to a specific enzyme, but is a universal platform technology with broad market application prospects.

[0019] Furthermore, the recombinant expression vector includes a plasmid.

[0020] This invention does not specifically limit the type of plasmid; any conventional plasmid can be used in this invention. Further, the plasmid includes, but is not limited to, any one of pET-21a(+), pET-28a(+), pET-22b(+), pET30a(+), or pET32a(+). Preferably, it is pET-30a(+).

[0021] Another aspect of the present invention relates to a recombinant bacterium, comprising: the recombinant expression vector.

[0022] The recombinant bacteria described are engineered strains capable of stably carrying and expressing the aforementioned recombinant vector. These strains can produce the target product, namely the self-aggregating immobilized enzyme, at low cost and high efficiency through large-scale fermentation, making the entire technology potentially suitable for industrial-scale production and a crucial step in moving from the laboratory to practical application.

[0023] Further, the recombinant expression vector is transformed into a host bacterium to obtain the recombinant bacterium.

[0024] This invention does not specifically limit the host bacteria; any conventional host bacteria in the art can be used to implement the technical solutions of this invention. Further, the host bacteria include, but are not limited to, at least one of: Escherichia coli, Bacillus subtilis, or Saccharomyces cerevisiae.

[0025] Another aspect of the invention relates to the use of the recombinant bacteria in any of the following: (1) Application in the production and expression of soluble proteins; (2) Application in immobilized soluble proteins; (3) Application in the production of products from catalytic substrates.

[0026] Another aspect of the invention relates to a self-aggregating immobilized enzyme, comprising the self-aggregating protein and the target protein.

[0027] The self-aggregating immobilized enzyme described herein automatically forms insoluble aggregates mediated by self-aggregating protein tags. This immobilized enzyme requires no exogenous carrier or chemical cross-linking agent, simplifying the preparation process, preserving the enzyme's native conformation and activity to the greatest extent, and is easily separated and recovered from the reaction system due to its physical form.

[0028] Furthermore, the connection sequence of the self-aggregating protein and the target protein is as follows: the self-aggregating protein connects to the target protein. This connection method can most effectively ensure the occurrence of self-aggregation behavior while minimizing spatial obstruction to the active site of the target enzyme, thereby ensuring that the final immobilized enzyme has the highest activity yield and catalytic efficiency.

[0029] Self-aggregating immobilized enzymes contain self-aggregating protein fragments that can aggregate intracellularly without the need for an exogenous immobilization vector; after the fusion protein self-aggregates, the target expressed enzyme remains in a free state. The self-aggregating protein exists as a precipitate, but the target enzyme protein remains in a free state.

[0030] Another aspect of the present invention relates to a method for preparing the self-aggregating immobilized enzyme, comprising the following steps: The recombinant bacteria were fermented.

[0031] Compared to traditional immobilization techniques that require multiple and complex immobilization steps followed by enzyme purification, the method of this invention achieves enzyme expression and immobilization "in situ" within cells through only one core step: fermentation culture of engineered bacteria. Subsequent simple cell disruption and centrifugation are all that's needed to obtain the immobilized enzyme product. This method significantly reduces production costs, time costs, and operational complexity, which is the core advantage of this invention for industrial application.

[0032] Furthermore, the OD of the fermentation system... 600 When the value is 15 to 20 (for example, it can be any point value of 15, 16, 17, 18, 19 or 20 or a range of any two), add an inducing agent.

[0033] Furthermore, the fermentation time is 15 to 24 hours, including but not limited to any one of 15 hours, 17 hours, 19 hours, 22 hours, or 24 hours, or a range between any two.

[0034] Further, the fermentation system is centrifuged to obtain wet cells containing self-aggregating and immobilized enzymes. The wet cells are then homogenized and broken to obtain a precipitate containing self-aggregating and immobilized enzymes.

[0035] Furthermore, the pressure for homogeneous crushing is 800~1000 bar, including but not limited to any one of 800 bar, 850 bar, 900 bar, 950 bar or 1000 bar or a range between any two.

[0036] Furthermore, the method for preparing the self-aggregating immobilized enzyme further includes: separating the self-aggregating immobilized enzyme precipitate, washing it, and obtaining pure immobilized enzyme.

[0037] Another aspect of the invention relates to the use of the self-aggregating protein or the self-aggregating immobilized enzyme in catalyzing biochemical reactions.

[0038] Furthermore, the biochemical reaction includes, but is not limited to, the synthesis of chiral amines, chiral alcohols, vanillin, or pharmaceutical intermediates.

[0039] Compared with the prior art, the beneficial effects of the present invention are as follows: (1) The self-aggregating protein provided by the present invention is endogenously immobilized without the need for an exogenous carrier: This self-aggregating protein has unique properties, and can spontaneously and efficiently aggregate to form an insoluble precipitate after expression in cells. This characteristic enables the enzyme immobilization process to be completed autonomously within the cell, completely eliminating the dependence of traditional immobilization technology on exogenous carriers, and fundamentally avoiding problems such as carrier cost, carrier biocompatibility, and steric hindrance of carrier to enzyme activity.

[0040] (2) The self-aggregating protein provided by this invention, as a universal "tag," can be linked to various target enzymes through gene fusion. Practice has proven that its fusion expression with various commonly used industrial enzymes can successfully achieve self-aggregation, demonstrating excellent universality and compatibility, thus becoming a universal immobilization technology platform. The protein aggregates formed after self-aggregation constitute a robust, water-insoluble natural protein matrix. This matrix provides a protective microenvironment for enzyme molecules, significantly enhancing the enzyme's tolerance to harsh external conditions (such as shear force, organic solvents, and pH fluctuations), thereby laying the foundation for the high stability of the immobilized enzyme.

[0041] (3) The self-aggregating immobilized enzyme provided by this invention, which is an immobilized enzyme prepared based on a specific self-aggregating protein, has a comprehensive performance far exceeding that of immobilized enzymes prepared by traditional methods, and is suitable for large-scale industrial applications. Traditional immobilization requires obtaining high-purity free enzymes first, and the purification process is costly and time-consuming. This invention only requires breaking engineered bacterial cells and centrifuging to directly obtain the immobilized enzyme from the precipitate, eliminating the complex and expensive enzyme purification process. The entire preparation process does not require the treatment of chemical cross-linking agents or complex embedding and adsorption operations, making the process simple and easy to scale up. Since the immobilization process is a mild physical aggregation rather than a drastic chemical modification, the natural spatial conformation of the enzyme molecule is maintained to the greatest extent.

[0042] (4) The immobilized enzymes prepared in this invention possess excellent mechanical and structural stability. After repeated use, the activities of various immobilized enzymes (such as isoeugenol monooxygenase, transaminase, etc.) can still be maintained at more than 80% of their initial activities. This characteristic greatly improves the efficiency of enzyme use, reduces the cost of enzymes per use, and lays the foundation for continuous production. The simplified preparation process reduces production costs, and the high enzyme activity retention and high operational stability improve process economy, making biocatalysis technology more competitive and promising in the large-scale industrial production of high-value-added chemicals such as chiral drug intermediates and fragrances (such as vanillin). Detailed Implementation

[0043] The technical solution of the present invention will be clearly and completely described below with reference to specific embodiments. However, those skilled in the art will understand that the embodiments described below are some embodiments of the present invention, but not all embodiments, and are only used to illustrate the present invention, and should not be regarded as limiting the scope of the present invention. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention. Where specific conditions are not specified in the embodiments, conventional conditions or conditions recommended by the manufacturer shall be followed. Where the manufacturers of reagents or instruments are not specified, they are all conventional products that can be purchased commercially.

[0044] The specific formulation of the culture medium involved in the embodiments of the present invention is as follows: Seed culture medium: consisting of 20 g / L glucose, 1.5 g / L yeast extract, 1.2 g / L peptone, 1.5 g / L (NH4)2SO4, 1.2 g / L K2HPO4, 0.8 g / L MgSO4, 1 g / L citric acid, 10 mg / L MnSO4·H2O, and 8 mg / L FeSO4·7H2O.

[0045] Fermentation medium: comprising 1.5 g / L anhydrous disodium hydrogen phosphate, 1.8 g / L potassium dihydrogen phosphate, 0.7 g / L ammonium chloride, 0.4 g / L anhydrous magnesium sulfate, 120 g / L glucose, 4 g / L peptone, 2.4 g / L yeast extract, 0.8 g / L anhydrous sodium sulfate, 30 mg / L manganese chloride tetrahydrate, 20 mg / L ferrous sulfate, 1 g / L citric acid, 2 mg / L vitamin mixture, and biotin. The vitamin mixture includes vitamins B1, B3, B5, and B12.

[0046] Example 1: Strain Construction Suzhou Genewise Biotechnology Co., Ltd. was commissioned to synthesize a gene sequence (target gene) encoding a self-aggregating protein and a target protein. The target gene was linked to pET30a, and the recombinant expression vector was transferred into BL21(DE3) to obtain recombinant bacteria.

[0047] Example 2: Fermentation and Preparation of Enzymes Using the recombinant E. coli BL21(DE3) / pET-30a- target gene constructed in Example 1, fermentation expression was performed according to the following steps: Plate activation: Dip an inoculation loop into the bacterial culture from the glycerol tube and streak it in four zones on an LB solid plate containing 500 μg / mL kanamycin. Incubate overnight in an inverted incubator at 37°C.

[0048] Activation in shaker: After plate activation in the above steps, pick large single clones and inoculate them into LB liquid medium containing 50 μg / mL kanamycin for activation. Then, streak the plates again on LB solid plates containing 50 μg / mL kanamycin. The plate should be used within one week.

[0049] Seed culture: Large single colonies were picked from solid plates and inoculated into seed culture medium containing 50 μg / mL kanamycin at a volume of 30 mL / 250 mL. The culture was carried out at 37°C and 200 rpm for 12 h to obtain the seed culture.

[0050] Fermentation culture: The seed culture was inoculated into a 10L fermenter at a 1% inoculum rate. 6L of fermentation medium (containing 50μg / mL kanamycin) was added. The initial culture temperature was 37℃. The pH was maintained at 7.0±0.2 by automatic addition of ammonia solution. The dissolved oxygen level was maintained at 30%~50% by adjusting the stirring speed or aeration rate. When the OD... 600 At 15°C, add IPTG inducer to a final concentration of 0.1 mM and lower the culture temperature to 30°C to begin fermentation. Maintain the glucose concentration in the tank at ≤0.5 g / L by feeding in an 80% glucose solution. OD 600 Set the value to 100, place the container in a tank to collect the bacteria, and obtain wet mycelium.

[0051] The wet bacterial cells were resuspended at a concentration of 20 wt%, homogenized, and centrifuged to obtain a precipitate, which is the self-aggregating immobilized enzyme (catalyst). The homogenization was performed three times at a pressure of 900 bar.

[0052] Example 3: Immobilized isoeugenol monooxygenase catalyzes the production of vanillin from isoeugenol. Immobilized isoeugenol monooxygenase was prepared using the method described in Example 2. This enzyme was then used to catalyze the conversion of isoeugenol to vanillin. The specific procedures are as follows: 0.5% (w / w) of the immobilized enzyme was suspended in 0.1M Tris 9.0, and 50 g / L isoeugenol was added. The reaction was allowed to proceed for 20 h, after which the reaction was stopped. The conversion rate was detected by HPLC. After each round, the immobilized enzyme was recovered and the next round of reaction was carried out. The results of the five repetitions are shown in Table 1. The enzyme activity was still >80% in the fifth repetition.

[0053] Table 1 Conversion rate at different repetition counts

[0054] Example 4: Immobilized transaminase catalyzes the production of R-α-phenylethylamine from acetophenone. An immobilized transaminase was prepared using the method described in Example 2. This enzyme was then used to catalyze the production of R-α-phenylethylamine from acetophenone. The specific procedures are as follows: Add 2 ml of 0.1 M PB7.0 to the reaction sphere, then add 150 mg of alanine, 1 mg of PLP, 330 mg of glucose, 2 mg of NAD(P), 50 g / L acetophenone, 1 wt of free lactate dehydrogenase, 1 wt of free glucose dehydrogenase, and 2 wt of immobilized transaminase in sequence. React at 30 °C for 20 h. HPLC is used to detect the conversion rate. After each round, the immobilized enzyme is recovered, and the next round of reaction is performed. The reaction is repeated 5 times. The results are shown in Table 2. The enzyme activity in the fifth reaction is still greater than 80% of the initial enzyme activity.

[0055] Table 2 Conversion Rate at Different Number of Repetitions

[0056] Example 5: Application of Immobilized Ketoreductase Immobilized ketone reductase was prepared using the method described in Example 2, and this enzyme was used to catalyze the generation of the iprocopran intermediate. The specific procedures are as follows: Add 5 ml of 0.1 M PB7.0 to the reaction sphere, then add 0.5 ml of DMSO, followed by 2 mg of NAD(P), 54 mg of glucose, and 1 g / L of substrate, then add 1 wt of free glucose dehydrogenase and 1 wt of immobilized ketone reductase. Incubate at 30 °C for 16–24 h. HPLC is used to detect the conversion rate. After each round, the immobilized enzyme is recovered, and the next round of reaction is performed. The reaction is repeated 5 times. The results are shown in Table 3. The enzyme activity in the fifth reaction is still greater than 70% of the initial enzyme activity.

[0057] Table 3 Conversion Rate at Different Number of Repetitions

[0058] Example 6: Application of Immobilized Glucose Dehydrogenase The immobilized glucose dehydrogenase prepared using the method in Example 2 was used to catalyze the production of R-α-phenylethylamine from acetophenone. The specific operation is as follows: Add 2 ml of 0.1 M PB7.0 to the reaction sphere, then add 150 mg of alanine, 1 mg of PLP, 330 mg of glucose, 2 mg of NAD(P), 50 g / L acetophenone, 1 wt of free lactate dehydrogenase, 0.01 wt of immobilized glucose dehydrogenase, and 2 wt of free transaminase in sequence. React at 30 °C for 20 h. HPLC is used to detect the conversion rate. After each round, the immobilized enzyme is recovered, and the next round of reaction is performed. The reaction is repeated 5 times. The results are shown in Table 4. The enzyme activity in the fifth reaction is still greater than 80% of the initial enzyme activity.

[0059] Table 4 Conversion Rate at Different Number of Repetitions

[0060] In summary, the data from Examples 3 to 6 consistently and strongly demonstrate the core advantages of the self-aggregating immobilized enzyme method described in this invention: This method possesses excellent versatility and is applicable to various key industrial enzymes such as monooxygenases, transaminases, ketone reductases, and glucose dehydrogenases; the prepared immobilized enzymes all exhibit extremely high initial catalytic activity, proving that the preparation process is mild and can maximize enzyme activity retention; more importantly, all immobilized enzymes demonstrate excellent operational stability, retaining most of their activity (most exceeding 80%) after five repeated uses, perfectly solving the key bottlenecks of severe enzyme activity loss and poor stability in traditional immobilization techniques. These data collectively support the significant progress of this invention in simplifying processes, reducing costs, and improving efficiency, providing a solid data foundation and feasibility proof for its large-scale application in industrial biocatalysis processes.

[0061] Although the present invention has been illustrated and described with specific embodiments, it should be understood that the above embodiments are only used to illustrate the technical solutions of the present invention, and not to limit them; those skilled in the art should understand that modifications can be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some or all of the technical features therein, without departing from the spirit and scope of the present invention; and these modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention; therefore, this means that all such substitutions and modifications that fall within the scope of the present invention are included in the appended claims.

Claims

1. A self-aggregating protein, characterized in that, The amino acid sequence of the self-aggregation protein is shown as SEQ ID NO.

1.

2. A recombinant expression vector, characterized in that, The recombinant expression vector comprises a nucleotide sequence encoding the self-aggregation protein of claim 1 and a nucleotide sequence encoding a target protein.

3. The recombinant expression vector of claim 2, wherein, The target protein comprises at least one of transaminase, ketoreductase, monooxygenase, ene-reductase, amino acid dehydrogenase, formic acid dehydrogenase or glucose dehydrogenase.

4. The recombinant expression vector of claim 2, wherein, The recombinant expression vector comprises a plasmid.

5. The recombinant expression vector of claim 4, wherein, The plasmid comprises any one of pET-21a(+), pET-28a(+), pET-22b(+), pET30a(+) or pET32a(+).

6. A recombinant bacterium, characterized in that, Comprising: The recombinant expression vector of any one of claims 2-5.

7. A self-aggregating immobilized enzyme characterized in that, The self-aggregation protein of claim 1 and a target protein.

8. The self-aggregating immobilized enzyme according to claim 7, characterized in that, The self-aggregation protein and the target protein are connected in the order of the self-aggregation protein connected to the target protein.

9. The method for preparing a self-aggregating immobilized enzyme according to claim 7 or 8, wherein Comprising the following steps: Fermenting the recombinant bacteria of claim 6.

10. Use of the self-aggregation protein of claim 1 or the self-aggregation immobilized enzyme of claim 7 or 8 in catalyzing a biochemical reaction.